Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A Cancer J Clin. 2019;69:280–304.

Google Scholar 

Piver MS. Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncol (Williston Park). 2006;20:1156–8.

Google Scholar 

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061.

Article  PubMed  Google Scholar 

Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer. Oncologist. 2021;26:e164–72.

Article  PubMed  CAS  Google Scholar 

Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 16:225–46.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–79.

Article  PubMed  PubMed Central  CAS  Google Scholar 

SEER [Internet]. [cited 2025 Apr 30]. Surveillance, Epidemiology, and End Results Program. Available from: https://seer.cancer.gov/index.html.

Cesur-Ergün B, Demir-Dora D. Gene therapy in cancer. J Gene Med. 2023;25:e3550.

Article  PubMed  Google Scholar 

Parker WB, Allan PW, Shaddix SC, Rose LM, Speegle HF, Gillespie GY, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharm. 1998;55:1673–81.

Article  PubMed  CAS  Google Scholar 

Janssens A, Boogaerts M, Verhoef G. Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia. Drug Des Devel Ther. 2009;3:241–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Behbahani TE, Rosenthal EL, Parker WB, Sorscher EJ. Intratumoral generation of 2‐fluoroadenine to treat solid malignancies of the head and neck. Head Neck. 2019;41:1979–83.

Article  PubMed  PubMed Central  Google Scholar 

Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem. 1998;273:2322–8.

Article  PubMed  CAS  Google Scholar 

Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother Pharm. 2012;70:321–9.

Article  CAS  Google Scholar 

Hong JS, Waud WR, Levasseur DN, Townes TM, Wen H, McPherson SA, et al. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 2004;64:6610–5.

Article  PubMed  CAS  Google Scholar 

Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther. 1997;4:577–85.

Article  PubMed  CAS  Google Scholar 

Parker WB, Allan PW, Hassan AEA, Secrist JA, Sorscher EJ, Waud WR. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003;10:23–9.

Article  PubMed  CAS  Google Scholar 

Nemunaitis J, Tong AW, Nemunaitis M, Senzer N, Phadke AP, Bedell C, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther. 2010;18:429–34.

Article  PubMed  CAS  Google Scholar 

Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis - ScienceDirect [Internet]. [cited 2024 May 2]Available from: https://www.sciencedirect.com/science/article/pii/S0169409X0900132X.

Sakaguchi M, Sadahira T, Ueki H, Kinoshita R, Murata H, Yamamoto KI, et al. Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements. Oncol Rep. 2017;38:1108–14.

Article  PubMed  CAS  Google Scholar 

Karjoo Z, Chen X, Hatefi A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 2016;99:113–28.

Article  PubMed  CAS  Google Scholar 

Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51:969–76.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ghanem R, Berchel M, Haute T, Buin X, Laurent V, Youf R, et al. Gene transfection using branched cationic amphiphilic compounds for an aerosol administration in cystic fibrosis context. Int J Pharm. 2023;631:122491.

Article  PubMed  CAS  Google Scholar 

Nguyen QM, Dupré PF, Berchel M, Ghanem R, Jaffrès PA, d’Arbonneau F, et al. BSV163/DOPE-mediated TRAIL gene transfection acts synergistically with chemotherapy against cisplatin-resistant ovarian cancer. Chemical Biology & Drug Design [Internet]. [cited 2023 Sep 26];n/a(n/a). Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/cbdd.14357.

Zhang Y, Toh L, Lau P, Wang X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. J Biol Chem. 2012;287:32494–511.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lindberg MF, Le Gall T, Carmoy N, Berchel M, Hyde SC, Gill DR, et al. Efficient in vivo transfection and safety profile of a CpG-free and codon optimized luciferase plasmid using a cationic lipophosphoramidate in a multiple intravenous administration procedure. Biomaterials. 2015;59:1–11.

Article  PubMed  CAS  Google Scholar 

Bouraoui A, Ghanem R, Berchel M, Deschamps L, Vié V, Paboeuf G, et al. Branched lipid chains to prepare cationic amphiphiles producing hexagonal aggregates: supramolecular behavior and application to gene delivery. Org Biomol Chem. 2020;18:337–45.

Article  PubMed  CAS  Google Scholar 

Tanida S, Mizoshita T, Ozeki K, Tsukamoto H, Kamiya T, Kataoka H, et al. Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol. 2012;2012:862879.

PubMed  PubMed Central  Google Scholar 

D’Amelio M, Cavallucci V, Cecconi F. Neuronal caspase-3 signaling: not only cell death. Cell Death Differ. 2010;17:1104–14.

Article  PubMed  Google Scholar 

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cong YS, Wright WE, Shay JW. Human Telomerase and Its Regulation. Microbiol Mol Biol Rev. 2002;66:407–25.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–91.

Article  PubMed  CAS  Google Scholar 

Nguyen QM, Dupré PF, Haute T, Montier T, d’Arbonneau F. Suicide gene strategies applied in ovarian cancer studies. Cancer Gene Ther. 2023;30:1–10.

Article  Google Scholar 

Parker WB, Sorscher EJ. Use of E. coli purine nucleoside phosphorylase in the treatment of solid tumors. CPD. 2018;23:7003–24.

Article  Google Scholar 

Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther. 1999;10:649–57.

Article  PubMed  CAS  Google Scholar 

Nestler U, Heinkelein M, Lücke M, Meixensberger J, Scheurlen W, Kretschmer A, et al. Foamy virus vectors for suicide gene therapy. Gene Ther. 1997;4:1270–7.

Article  PubMed  CAS